1338728-29-2

Upstream product

• 1338728-26-9 (4aR,6S,7R,8R,8aS)-6-(2-(allyloxy)-4-chloro-5-(4-ethoxybenzyl)phenyl)-2-vinylhexahydropyrano[3,2-d][1,3]dioxine-7,8-diol 
• 1338728-27-0 (2S,3R,4R,5S,6R)-2-(2-(allyloxy)-4-chloro-5-(4-ethoxybenzyl)phenyl)-6-(allyloxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1338728-28-1 (2S,3S,4R,5R,6R)-2-(2-(allyloxy)-4-chloro-5-(4-ethoxybenzyl)phenyl)-6-(allyloxymethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1006590-10-8 (5-bromo-2-chloro-4-methoxyphenyl)(4-ethoxyphenyl)methanone 
• 1338728-11-2 2-bromo-5-chloro-4-(4-ethoxybenzyl)phenol 
• 1338728-12-3 1-(allyloxy)-2-bromo-5-chloro-4-(4-ethoxybenzyl)benzene 
• 3336-16-1 2-chloro-4-hydroxybenzonitrile 
• 1338728-14-5 (3R,4R,5S,6R )-2-(2-(allyloxy)-4-chloro-5-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1338728-13-4 (3R,4S,5S,6R)-2-(2-(allyloxy)-4-chloro-5-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 1338728-16-7 (2S,3R,4R,5S,6R)-2-(2-(allyloxy)-4-chloro-5-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1338728-15-6 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(2-(allyloxy)-4-chloro-5-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1259020-48-8 5-bromo-2-chloro-4-methoxybenzoic acid 
• 1259020-79-5 5-bromo-2-chloro-4-methoxybenzonitrile 
• 1259020-46-6 5-bromo-2-chloro-4-hydroxybenzonitrile 

Downstream Products

• 1338728-30-5 (8R,9S,10R,11R,12S)-15-chloro-14-(4-ethoxybenzyl)-5,7,8,9,10,11,12-heptahydro-2H-8,12-epoxybenzo[g][1,6]dioxacyclotetradecine-9,10,11-triol 

Relevant academic research and scientific papers

Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents

Novel macrocyclic C-aryl glucoside SGLT2 inhibitors were designed and synthesized. Two different synthetic routes of macrocyclization were adopted to prepare novel ansa SGLT2 inhibitors. Among the compounds tested, [1,7]dioxacyclopentadecine macrocycles p